Amedisys (AMED) Q2 Revenue Tops 5%

Amedisys (AMED) reported strong operational performance in Q2 2025, with GAAP revenue of $621.9 million and Non-GAAP EPS of $1.54, both exceeding analyst expectations. However, GAAP net income declined to $28.1 million, down 13% year-over-year, primarily due to $26.3 million in expenses related to its pending merger with UnitedHealth Group. The company did not provide forward financial guidance, citing the ongoing merger, emphasizing that the transaction's outcome and future regulatory policy remain critical determinants for investors.

Analysis

Amedisys reported a bifurcated second quarter for 2025, demonstrating strong underlying operational performance that was materially obscured by costs and uncertainty related to its pending acquisition by UnitedHealth Group. The company surpassed consensus estimates with GAAP revenue of $621.9 million, a 5.2% year-over-year increase, and a Non-GAAP EPS of $1.54, which was 13.2% above analyst forecasts. Core profitability showed marked improvement, with Adjusted EBITDA climbing 10.3% to $80.8 million, signaling enhanced operating efficiency. However, these positive operational metrics were countered by a 13.0% decline in GAAP net income to $28.1 million, a direct consequence of incurring $26.3 million in merger-related expenses. The company also showed improved working capital management, as Days Revenue Outstanding fell from 52.1 to 40.9. Critically, management created a significant information vacuum by forgoing forward guidance and an earnings call, explicitly citing "significant regulatory and completion risks" associated with the merger. This leaves the investment thesis almost entirely dependent on the M&A outcome, with operational strength serving as a secondary consideration.

Key Decisions for Investors

• Investors should primarily evaluate Amedisys as a merger arbitrage opportunity, as its stock performance is now overwhelmingly dependent on the regulatory approval and successful completion of the UnitedHealth Group acquisition.
• The strong underlying operational results, including a 10.3% increase in Adjusted EBITDA and improved cash collections, provide a degree of fundamental support that should be monitored as a potential valuation floor if the merger fails.
• Given the absence of forward guidance and management's explicit warning of significant completion risk, investors must prioritize tracking regulatory announcements and antitrust commentary over traditional fundamental analysis for the foreseeable future.